NCT06558084View on ClinicalTrials.gov

Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy

CompletedOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

August 10, 2024

Conditions
Toxicity, DrugProgression, Disease
Interventions
DRUG

CDK4/6 Inhibitor

CDK4/6 inhibitor in first and second lines

Trial Locations (1)

Unknown

Ainshams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER